TIMI-AF score and cardiovascular events in vitamin K antagonists-naïve outpatients with atrial fibrillation

Alejandro Isidoro Pérez Cabeza, Rafael Bravo Marques, Pedro Antonio Chinchurreta Capote, Francisco Ruiz Mateas, Christina L. Fanola, Gabriel Rosas Cervantes, Jose Antonio González Correa, Almudena Valle Alberca, Fidel Mesa Prado, Sergio López Tejero, Christian Thomas Ruff

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Background: The TIMI-AF score predicts poor outcomes in patients with atrial fibrillation (AF) and guides selection of anticoagulant therapy by identifying clinical benefit of direct oral anticoagulants (DOACs) or vitamin K antagonists (VKA). Hypothesis: Our objective was to determine the ability to predict cardiovascular events according to the TIMI-AF score in a real-world population. Methods: Retrospective observational study of VKA-naïve patients with AF was seen at a cardiology outpatient clinic in Spain between November 2012 and August 2014. We recorded adverse events (myocardial infarction, systemic embolism or stroke, major bleeding, and death). Results: The study population comprised of 426 patients (50.7% men, mean age, 69 ± 14 years). The TIMI-AF score identified 372 patients (87.3%) with a low risk, 50 patients (11.7%) with an intermediate risk, and 4 patients (0.9%) with a high risk. After a mean follow-up of 423.4 ± 200.1 days, 37 patients (9%) experienced an adverse event. Patients with a TIMI-AF score ≥ 7 had a poorer cardiovascular prognosis (HR, 6.1; 95%CI, 3.2-11.7; P < 0.001). The area under the ROC curve of TIMI-AF was 0.755 (95%CI, 0.669-0.840; P < 0.001), which was greater than that of CHA2DS2VASc (0.641; 95%CI, 0.559-0.724; P = 0.004), HAS-BLED (0.666; 95%CI, 0.578-0.755; P < 0.001), and SAMeTT2R2 (0.529; 95%CI, 0.422-0.636; P = 0.565). Similar results were obtained in relation to the net clinical outcome (life-threatening bleeding, disabling stroke, or all-cause mortality). Conclusions: The TIMI-AF risk score can identify patients who are at greater risk of cardiovascular events and a poor net clinical outcome with a better diagnostic yield than CHA2DS2VASc, HAS-BLED, and SAMeTT2R2.

Original languageEnglish (US)
Pages (from-to)1252-1258
Number of pages7
JournalClinical Cardiology
Volume41
Issue number9
DOIs
StatePublished - Sep 2018

Bibliographical note

Funding Information:
We want to thank Dr. Jorge Andr?s Mu?oz Robles and Carlos Ramos Ortiz for their support and wise advice. Dr. Christian T. Ruff received honoraria from Daiichi Sankyo, Boehringer ingelheim, Bayer and Portola as a consultant and received research grants from Daichii Sankyo. Dr. Alejandro I. P?rez Cabeza received honoraria from Daiichi Sankyo and Bayer as a consultant. Dr. Francisco Ruiz Mateas received honoraria from Bayer and Boehringer ingelheim as a consultant.

Funding Information:
Dr. Christian T. Ruff received honoraria from Daiichi Sankyo, Boehringer ingelheim, Bayer and Portola as a consultant and received research grants from Daichii Sankyo. Dr. Alejandro I. Pérez Cabeza received honoraria from Daiichi Sankyo and Bayer as a consultant. Dr. Francisco Ruiz Mateas received honoraria from Bayer and Boehringer ingelheim as a consultant.

Publisher Copyright:
© 2018 Wiley Periodicals, Inc.

Keywords

  • TIMI-AF score
  • anticoagulants
  • atrial fibrillation
  • cardiovascular prognosis

Fingerprint

Dive into the research topics of 'TIMI-AF score and cardiovascular events in vitamin K antagonists-naïve outpatients with atrial fibrillation'. Together they form a unique fingerprint.

Cite this